Hanx Biopharmaceuticals’ HX009 Receives US IND Approval for Lymphoma Treatment
Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND)...
Innovent Biologics
Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults
China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing...
Innovent Biologics’ Tyvyt Secures NMPA Approval for EGFR-Mutated NSCLC Treatment
China-based Innovent Biologics Inc., (HKG: 1801) has announced that the National Medical Products Administration (NMPA)...
Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...
Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD...
Innovent Biologics Begins Phase I Trial for IBI333 in Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Innovent Biologics Posts Strong Q4 Revenues Amid COVID-19 Challenges
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Legend Biotech’s Carvykti Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) website indicates that a market approval filing from Legend...
Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation
China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...
IASO Biotherapeutics Receives FDA Approval for CT103A IND Application
China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...
Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance
China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...
Innovent Biologics Collaborates with LG Chem for Tigulixostat in China
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...